Activation	0	10	O
of	11	13	O
vascular	14	22	B-Gene_or_gene_product
endothelial	23	34	I-Gene_or_gene_product
growth	35	41	I-Gene_or_gene_product
factor	42	48	I-Gene_or_gene_product
through	49	56	O
reactive	57	65	O
oxygen	66	72	B-Drug_or_compound
species	73	80	O
mediates	81	89	O
20	90	92	B-Drug_or_compound
-	92	93	I-Drug_or_compound
hydroxyeicosatetraenoic	93	116	I-Drug_or_compound
acid	117	121	I-Drug_or_compound
-	121	122	O
induced	122	129	O
endothelial	130	141	B-Cell
cell	142	146	I-Cell
proliferation	147	160	O
.	160	161	O

20	163	165	B-Drug_or_compound
-	165	166	I-Drug_or_compound
Hydroxyeicosatetraenoic	166	189	I-Drug_or_compound
acid	190	194	I-Drug_or_compound
(	195	196	O
20	196	198	B-Drug_or_compound
-	198	199	I-Drug_or_compound
HETE	199	203	I-Drug_or_compound
)	203	204	O
is	205	207	O
formed	208	214	O
by	215	217	O
the	218	221	O
omega	222	227	O
-	227	228	O
hydroxylation	228	241	O
of	242	244	O
arachidonic	245	256	B-Drug_or_compound
acid	257	261	I-Drug_or_compound
by	262	264	O
cytochrome	265	275	B-Gene_or_gene_product
P450	276	280	I-Gene_or_gene_product
4A	281	283	I-Gene_or_gene_product
and	284	287	O
4F	288	290	B-Gene_or_gene_product
enzymes	291	298	O
,	298	299	O
and	300	303	O
it	304	306	O
induces	307	314	O
angiogenic	315	325	O
responses	326	335	O
in	336	338	O
vivo	339	343	O
.	343	344	O

To	345	347	O
test	348	352	O
the	353	356	O
hypothesis	357	367	O
that	368	372	O
20	373	375	B-Drug_or_compound
-	375	376	I-Drug_or_compound
HETE	376	380	I-Drug_or_compound
increases	381	390	O
endothelial	391	402	B-Cell
cell	403	407	I-Cell
(	408	409	O
EC	409	411	B-Cell
)	411	412	O
proliferation	413	426	O
via	427	430	O
vascular	431	439	B-Gene_or_gene_product
endothelial	440	451	I-Gene_or_gene_product
growth	452	458	I-Gene_or_gene_product
factor	459	465	I-Gene_or_gene_product
(	466	467	O
VEGF	467	471	B-Gene_or_gene_product
)	471	472	O
,	472	473	O
we	474	476	O
studied	477	484	O
the	485	488	O
effects	489	496	O
of	497	499	O
WIT003	500	506	B-Drug_or_compound
[	507	508	O
20	508	510	B-Drug_or_compound
-	510	511	I-Drug_or_compound
hydroxyeicosa	511	524	I-Drug_or_compound
-	524	525	I-Drug_or_compound
5	525	526	I-Drug_or_compound
(	526	527	I-Drug_or_compound
Z	527	528	I-Drug_or_compound
)	528	529	I-Drug_or_compound
,	529	530	I-Drug_or_compound
14	530	532	I-Drug_or_compound
(	532	533	I-Drug_or_compound
Z	533	534	I-Drug_or_compound
)	534	535	I-Drug_or_compound
-	535	536	I-Drug_or_compound
dienoic	536	543	I-Drug_or_compound
acid	544	548	I-Drug_or_compound
]	548	549	O
,	549	550	O
a	551	552	O
20	553	555	B-Drug_or_compound
-	555	556	I-Drug_or_compound
HETE	556	560	I-Drug_or_compound
analog	561	567	O
on	568	570	O
human	571	576	B-Organism
macrovascular	577	590	B-Cell
or	591	593	O
microvascular	594	607	B-Cell
EC	608	610	I-Cell
.	610	611	O

WIT003	612	618	B-Drug_or_compound
,	618	619	O
as	620	622	O
well	623	627	O
as	628	630	O
pure	631	635	O
20	636	638	B-Drug_or_compound
-	638	639	I-Drug_or_compound
HETE	639	643	I-Drug_or_compound
,	643	644	O
stimulated	645	655	O
EC	656	658	B-Cell
proliferation	659	672	O
by	673	675	O
approximately	676	689	O
40	690	692	O
%	692	693	O
.	693	694	O

These	695	700	O
proliferative	701	714	O
effects	715	722	O
were	723	727	O
accompanied	728	739	O
by	740	742	O
increased	743	752	O
VEGF	753	757	B-Gene_or_gene_product
expression	758	768	O
and	769	772	O
release	773	780	O
that	781	785	O
were	786	790	O
observed	791	799	O
as	800	802	O
early	803	808	O
as	809	811	O
4	812	813	O
h	814	815	O
after	816	821	O
20	822	824	B-Drug_or_compound
-	824	825	I-Drug_or_compound
HETE	825	829	I-Drug_or_compound
agonist	830	837	O
addition	838	846	O
.	846	847	O

This	848	852	O
was	853	856	O
accompanied	857	868	O
by	869	871	O
increased	872	881	O
phosphorylation	882	897	O
of	898	900	O
the	901	904	O
VEGF	905	909	B-Gene_or_gene_product
receptor	910	918	I-Gene_or_gene_product
2	919	920	I-Gene_or_gene_product
.	920	921	O

The	922	925	O
proliferative	926	939	O
effects	940	947	O
of	948	950	O
20	951	953	B-Drug_or_compound
-	953	954	I-Drug_or_compound
HETE	954	958	I-Drug_or_compound
were	959	963	O
markedly	964	972	O
inhibited	973	982	O
by	983	985	O
a	986	987	O
VEGF	988	992	B-Gene_or_gene_product
-	992	993	O
neutralizing	993	1005	O
antibody	1006	1014	O
.	1014	1015	O

Polyethylene	1016	1028	B-Drug_or_compound
glycol	1029	1035	I-Drug_or_compound
-	1035	1036	I-Drug_or_compound
superoxide	1036	1046	I-Drug_or_compound
dismutase	1047	1056	I-Drug_or_compound
(	1057	1058	O
PEG	1058	1061	B-Drug_or_compound
-	1061	1062	I-Drug_or_compound
SOD	1062	1065	I-Drug_or_compound
)	1065	1066	O
markedly	1067	1075	O
inhibited	1076	1085	O
both	1086	1090	O
the	1091	1094	O
increases	1095	1104	O
in	1105	1107	O
VEGF	1108	1112	B-Gene_or_gene_product
expression	1113	1123	O
and	1124	1127	O
the	1128	1131	O
proliferative	1132	1145	O
effects	1146	1153	O
of	1154	1156	O
20	1157	1159	B-Drug_or_compound
-	1159	1160	I-Drug_or_compound
HETE	1160	1164	I-Drug_or_compound
.	1164	1165	O

In	1166	1168	O
contrast	1169	1177	O
,	1177	1178	O
administration	1179	1193	O
of	1194	1196	O
the	1197	1200	O
NAD	1201	1204	B-Gene_or_gene_product
(	1204	1205	I-Gene_or_gene_product
P	1205	1206	I-Gene_or_gene_product
)	1206	1207	I-Gene_or_gene_product
H	1207	1208	I-Gene_or_gene_product
oxidase	1209	1216	I-Gene_or_gene_product
inhibitor	1217	1226	O
apocynin	1227	1235	B-Drug_or_compound
had	1236	1239	O
no	1240	1242	O
effect	1243	1249	O
to	1250	1252	O
the	1253	1256	O
proliferative	1257	1270	O
response	1271	1279	O
to	1280	1282	O
20	1283	1285	B-Drug_or_compound
-	1285	1286	I-Drug_or_compound
HETE	1286	1290	I-Drug_or_compound
.	1290	1291	O

The	1292	1295	O
20	1296	1298	B-Drug_or_compound
-	1298	1299	I-Drug_or_compound
HETE	1299	1303	I-Drug_or_compound
agonist	1304	1311	O
markedly	1312	1320	O
increased	1321	1330	O
superoxide	1331	1341	B-Drug_or_compound
formation	1342	1351	O
as	1352	1354	O
reflected	1355	1364	O
by	1365	1367	O
an	1368	1370	O
increase	1371	1379	O
in	1380	1382	O
dihydroethidium	1383	1398	B-Drug_or_compound
staining	1399	1407	O
of	1408	1410	O
EC	1411	1413	B-Cell
,	1413	1414	O
and	1415	1418	O
this	1419	1423	O
increase	1424	1432	O
was	1433	1436	O
inhibited	1437	1446	O
by	1447	1449	O
PEG	1450	1453	B-Drug_or_compound
-	1453	1454	I-Drug_or_compound
SOD	1454	1457	I-Drug_or_compound
but	1458	1461	O
not	1462	1465	O
by	1466	1468	O
apocynin	1469	1477	B-Drug_or_compound
.	1477	1478	O

20	1479	1481	B-Drug_or_compound
-	1481	1482	I-Drug_or_compound
HETE	1482	1486	I-Drug_or_compound
also	1487	1491	O
increased	1492	1501	O
the	1502	1505	O
phosphorylation	1506	1521	O
of	1522	1524	O
p42	1525	1528	B-Gene_or_gene_product
/	1528	1529	I-Gene_or_gene_product
p44	1529	1532	I-Gene_or_gene_product
mitogen	1533	1540	I-Gene_or_gene_product
-	1540	1541	I-Gene_or_gene_product
activated	1541	1550	I-Gene_or_gene_product
protein	1551	1558	I-Gene_or_gene_product
kinase	1559	1565	I-Gene_or_gene_product
(	1566	1567	O
MAPK	1567	1571	B-Gene_or_gene_product
)	1571	1572	O
in	1573	1575	O
EC	1576	1578	B-Cell
,	1578	1579	O
whereas	1580	1587	O
an	1588	1590	O
inhibitor	1591	1600	O
of	1601	1603	O
MAPK	1604	1608	B-Gene_or_gene_product
[	1609	1610	O
U0126	1610	1615	B-Drug_or_compound
,	1615	1616	O
1	1617	1618	B-Drug_or_compound
,	1618	1619	I-Drug_or_compound
4	1619	1620	I-Drug_or_compound
-	1620	1621	I-Drug_or_compound
diamino	1621	1628	I-Drug_or_compound
-	1628	1629	I-Drug_or_compound
2	1629	1630	I-Drug_or_compound
,	1630	1631	I-Drug_or_compound
3	1631	1632	I-Drug_or_compound
-	1632	1633	I-Drug_or_compound
dicyano	1633	1640	I-Drug_or_compound
-	1640	1641	I-Drug_or_compound
1	1641	1642	I-Drug_or_compound
,	1642	1643	I-Drug_or_compound
4	1643	1644	I-Drug_or_compound
-	1644	1645	I-Drug_or_compound
bis	1645	1648	I-Drug_or_compound
(	1648	1649	I-Drug_or_compound
2	1649	1650	I-Drug_or_compound
-	1650	1651	I-Drug_or_compound
aminophenylthio	1651	1666	I-Drug_or_compound
)	1666	1667	I-Drug_or_compound
butadiene	1667	1676	I-Drug_or_compound
]	1676	1677	O
suppressed	1678	1688	O
the	1689	1692	O
proliferative	1693	1706	O
and	1707	1710	O
the	1711	1714	O
VEGF	1715	1719	B-Gene_or_gene_product
changes	1720	1727	O
but	1728	1731	O
not	1732	1735	O
the	1736	1739	O
pro	1740	1743	O
-	1743	1744	O
oxidant	1744	1751	O
effects	1752	1759	O
of	1760	1762	O
20	1763	1765	B-Drug_or_compound
-	1765	1766	I-Drug_or_compound
HETE	1766	1770	I-Drug_or_compound
.	1770	1771	O

These	1772	1777	O
data	1778	1782	O
suggest	1783	1790	O
that	1791	1795	O
20	1796	1798	B-Drug_or_compound
-	1798	1799	I-Drug_or_compound
HETE	1799	1803	I-Drug_or_compound
stimulates	1804	1814	O
superoxide	1815	1825	B-Drug_or_compound
formation	1826	1835	O
by	1836	1838	O
pathways	1839	1847	O
other	1848	1853	O
than	1854	1858	O
apocynin	1859	1867	B-Drug_or_compound
-	1867	1868	O
sensitive	1868	1877	O
NAD	1878	1881	B-Gene_or_gene_product
(	1881	1882	I-Gene_or_gene_product
P	1882	1883	I-Gene_or_gene_product
)	1883	1884	I-Gene_or_gene_product
H	1884	1885	I-Gene_or_gene_product
oxidase	1886	1893	I-Gene_or_gene_product
,	1893	1894	O
thereby	1895	1902	O
activating	1903	1913	O
MAPK	1914	1918	B-Gene_or_gene_product
and	1919	1922	O
then	1923	1927	O
enhancing	1928	1937	O
VEGF	1938	1942	B-Gene_or_gene_product
synthesis	1943	1952	O
that	1953	1957	O
drives	1958	1964	O
EC	1965	1967	B-Cell
proliferation	1968	1981	O
.	1981	1982	O

Thus	1983	1987	O
,	1987	1988	O
20	1989	1991	B-Drug_or_compound
-	1991	1992	I-Drug_or_compound
HETE	1992	1996	I-Drug_or_compound
may	1997	2000	O
be	2001	2003	O
involved	2004	2012	O
in	2013	2015	O
the	2016	2019	O
regulation	2020	2030	O
of	2031	2033	O
EC	2034	2036	B-Cell
functions	2037	2046	O
,	2046	2047	O
such	2048	2052	O
as	2053	2055	O
angiogenesis	2056	2068	O
.	2068	2069	O

